Inclusion Criteria:  Documented diagnosis of Myelodysplastic syndrome, Acute myeloid leukemia, Multiple myeloma, Non-Hodgkin's lymphoma, Hodgkin's lymphoma or metastatic or inoperable solid tumors Life expectancy of ≥ 3 months Stable renal function without dialysis for at least 2 months prior to investigational product administration Has moderate or severe hepatic impairment as defined by National Cancer Institute Organ Dysfunction Working Group criteria  Exclusion Criteria:  Chemotherapy or radiotherapy within 4 weeks prior to the first day of investigational product administration Persistent, clinically significant non-hematologic toxicities from prior therapies which have not recovered to < Grade 2 Any condition including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the study History of inflammatory bowel disease, celiac disease, prior gastrectomy, gastric bypass, upper bowel removal, or any other gastrointestinal disorder or defect that would interfere with the absorption of the investigational product and/or predispose the participant to an increased risk of gastrointestinal toxicity  Other protocol-defined inclusion/exclusion criteria apply